No Access To EMA Documents For Non-EU Entities As Requests Get Excessively Burdensome
The European Medicines Agency is facing excessive workload because of high volumes of access to document requests, and has decided not to process requests coming from outside of the EU.
You may also be interested in...
When the European Medicines Agency was drafting its policy on the proactive publication of clinical trial data, one concern expressed by the R&D industry was that the documents released might be of benefit to competitor companies, particularly if they contained commercially confidential information.
As part of efforts to “renovate” its good clinical practice (GCP) framework, the International Council for Harmonisation has framed new overarching GCP principles that can be applied to diverse trial types and data sources.
The 2021 work plan of PIC/S, the international group of pharmaceutical inspectorates, includes renewed efforts to carry out projects that could not be completed due to the coronavirus pandemic.